Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;68(1):190-2.
doi: 10.1093/jac/dks363. Epub 2012 Sep 13.

Mutations selected in HIV-2-infected patients failing a regimen including atazanavir

Joana Cavaco-Silva  1 , Maria João Aleixo, Kristel Van Laethem, Domitília Faria, Emília Valadas, Maria de Fátima Gonçalves, Perpétua Gomes, Anne-Mieke Vandamme, Celso Cunha, Ricardo Jorge Camacho; Portuguese HIV-2 Resistance Study Group
Collaborators, Affiliations

Mutations selected in HIV-2-infected patients failing a regimen including atazanavir

Joana Cavaco-Silva et al. J Antimicrob Chemother. 2013 Jan.

Abstract

Objectives: To investigate mutations selected in viruses from HIV-2-infected patients failing a highly active antiretroviral treatment (HAART) regimen including atazanavir/ritonavir.

Methods: Twenty-eight HIV-2-infected patients previously exposed to atazanavir/ritonavir and failing therapy were studied. The protease (PR) gene was amplified and sequenced, and mutations emerging under atazanavir/ritonavir selective pressure were reported.

Results: The I50L mutation emerged in 4 out of 28 HIV-2-infected patients failing a HAART regimen including atazanavir/ritonavir. Besides I50L, four PR mutations previously associated with protease inhibitor resistance (I54L, I64V, V71I and I82F) and six PR mutations of unknown impact (V10I, E37D, S43T, K45R, I75V and F85L) in HIV-2 were also identified in this small group of patients.

Conclusions: Several mutations were associated with virological failure of a regimen including atazanavir/ritonavir in HIV-2-infected patients, including I50L for the first time. It should be included in HIV-2 algorithms for interpretation of genotypic resistance data, and taken into account when making therapeutic decisions for HIV-2-infected patients.

PubMed Disclaimer

Publication types